Beam Therapeutics Inc. (NASDAQ: BEAM) reported that Chief Executive Officer John M. Evans disposed of 30,078 shares of common stock on April 1, 2026, at $24.58 per share, for aggregate proceeds of roughly $739,317. The transaction price was close to the companys quoted level of $24.23, a price that reflects a 59% gain over the prior 12 months despite recent share-price volatility.
Details filed on a Form 4 with the Securities and Exchange Commission indicate the sale was executed to cover tax-withholding obligations arising from the vesting of restricted stock units. The disposition was carried out automatically under a Rule 10b5-1 trading plan that Evans adopted on May 19, 2023, according to the filing.
Following the sale, Evans holds 1,047,205 shares directly. That total includes 616 shares he acquired through the companys Employee Stock Purchase Plan on March 31, 2026. In addition to his direct holdings, Evans has an indirect stake of 103,000 shares held through the John M. Evans, III 2018 Irrevocable Trust.
Valuation and balance-sheet notes
An InvestingPro analysis cited in the company disclosure indicates that BEAM is trading below its calculated Fair Value, implying potential upside from the analyst panels perspective. The same analysis highlights the companys balance sheet position as having more cash than debt. InvestingPro also references further research content including additional ProTips and detailed reports available through its subscription service.
Clinical updates and analyst responses
Beam concurrently released clinical data from its Phase 1/2 programs. The BEACON trial for risto-cel in sickle cell disease included 31 patients with severe vaso-occlusive crises and reported follow-up times reaching up to 20.4 months. Separately, Beam announced results for BEAM-302 in alpha-1 antitrypsin deficiency, identifying 60 mg as the dose to advance into pivotal development.
Those clinical updates drew multiple analyst actions. Bernstein SocGen Group reiterated an Outperform rating and maintained a $40 price target, citing improvements in serum AAT levels. Leerink Partners raised its price target to $47 and kept an Outperform rating based on updated Phase 1/2 data. William Blair reiterated an Outperform rating while highlighting the highest mean serum AAT level observed clinically with BEAM-302. Clear Street retained a Buy rating and a $37 target, noting confirmation of the dose for pivotal development.
Collectively, the insider stock sale and the clinical disclosures provide investors with contemporaneous information on managements personal tax-driven liquidity move and on the companys advancing clinical programs and external analyst assessments.